Yin Yang 1 in Human cancer

Critical Reviews in Oncogenesis

Volumn 16, Issue 3-4, 2011, Pages 245-260

  Nicholson, Sarah ^a   Whitehouse, Helen ^a   Naidoo, Khimara ^b   Byers, Richard J ^a,c  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Apoptosis; Carcinogenesis; Cell cycle; Human cancer; Prognosis; Yin yang 1

Indexed keywords

TRANSCRIPTION FACTOR YY1;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; BRAIN CANCER; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE REGULATION; CELL PROLIFERATION; COLON CANCER; COLON CARCINOMA; GENE EXPRESSION REGULATION; HUMAN; LEUKEMIA; LYMPHOMA; METASTASIS; NEOPLASM; OSTEOSARCOMA; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; RHABDOMYOSARCOMA; UTERINE CERVIX CANCER;

EID: 84855846679     PISSN: 08939675     EISSN: 21626448     Source Type: Journal    
DOI: 10.1615/CritRevOncog.v16.i3-4.80     Document Type: Review

References (57)

1. Gordon S, Akopyan G, Garban H, Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Onco-gene. 2006;25(8):1125-1142.
2. Naidoo K, Byers RJ. YY1 as a therapeutic target in cancer. For Immunopathol Dis Terap. 2010;2010(1-2):51-64.
3. Castellano G, Torrisi E, Ligresti G, Malaponte G, Militello L, Russo AE, McCubrey JA, Canevari S, Libra M. Te involvement of the transcription factor Yin Yang 1 in cancer development and progression. Cell Cycle. 2009;8(9):1367-1372.
4. Hsieh SY, Zhuang FH, Wu Y T, Chen JK, Lee YL. Profling the proteome dynamics during the cell cycle of human hepatoma cells. Proteomics. 2008;8(14):2872-2884.
5. Rizkallah R, Alexander KE, Kassardjian A, Luscher B, Hurt MM. Te transcription factor YY1 is a substrate for Polo-like kinase 1 at the G2/M transition of the cell cycle. PLoS One. 2011;6(1):e15928.
6. Lane DP. p53 and human cancers. Br Med Bull. 1994;50(3):582-599.
7. Gronroos E, Terentiev AA, Punga T, Ericsson J. YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress. Proc Natl Acad Sci U S A. 2004;101(33):12165-12170.
8. Sui G, Afar el B, Shi Y, Brignone C, Wall NR, Yin P, Donohoe M, Luke MP, Calvo D, Grossman SR. Yin Yang 1 is a negative regulator of p53. Cell. 2004;117(7):859-872.
9. Petkova V, Romanowski MJ, Sulijoadikusumo I, Rohne D, Kang P, Shenk T, Usheva A. Interaction between YY1 and the retinoblastoma protein. Regulation of cell cycle progression in diferentiated cells. J Biol Chem. 2001;276(11):7932-7936.
10. Riggs KJ, Saleque S, Wong KK, Merrell KT, Lee JS, Shi Y, Calame K. Yin-yang 1 activates the c-myc promoter. Mol Cell Biol. 1993;13(12):7487-7495.
11. Shrivastava A, Yu J, Artandi S, Calame K. YY1 and c-Myc associate in vivo in a manner that depends on c-Myc levels. Proc Natl Acad Sci U S A. 1996;93(20):10638-10641.
12. MacFarlane M, Williams AC. Apoptosis and disease: a life or death decision. EMBO Rep. 2004;5(7):674-678.
13. Irmler M, Tome M, Hahne M, Schneider P, Hof-mann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J. Inhibition of death receptor signals by cellular FLIP. Nature. 1997;388(6638):190-195.
14. Karantzoulis-Fegaras F, Antoniou H, Lai SL, Kulkarni G, D'Abreo C, Wong GK, Miller TL, Chan Y, Atkins J, Wang Y, Marsden PA. Characterization of the human endothelial nitric-oxide synthase promoter. J Biol Chem. 1999;274(5):3076-3093.
15. Garban HJ, Bonavida B. Nitric oxide inhibits the transcription repressor Yin-Yang 1 binding activity at the silencer region of the Fas promoter: a pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells. J Immunol. 2001;167(1):75-81.
16. Huerta-Yepez S, Vega M, Garban H, Bonavida B. Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis. Clin Immunol. 2006;120(3):297-309.
17. Vega MI, Huerta-Yepez S, Jazirehi AR, Garban H, Bonavida B. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene. 2005;24(55):8114-8127.
18. Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res. 2005;65(1):264-276.
19. Vega MI, Jazirehi AR, Huerta-Yepez S, Bonavida B. Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively. J Immunol. 2005;175(4):2174-2183.
20. Zaravinos A, Spandidos DA. Yin yang 1 expression in human tumors. Cell Cycle. 2010;9(3):512-522.
21. Sakhinia E, Glennie C, Hoyland JA, Menasce LP, Brady G, Miller C, Radford JA, Byers RJ. Clinical quantitation of diagnostic and predictive gene expression levels in follicular and difuse large B-cell lymphoma by RT-PCR gene expression profling. Blood. 2007;109(9):3922-3928.
22. Naidoo K, Clay V, Hoyland JA, Swindell R, Linton K, Illidge T, Radford JA, Byers RJ. YY1 expression predicts favourable outcome in follicular lymphoma. J Clin Pathol. 2011;64(2):125-129.
23. Yao YL, Yang WM, Seto E. Regulation of transcription factor YY1 by acetylation and deacetylation. Mol Cell Biol. 2001;21(17):5979-5991.
24. Castellano G, Torrisi E, Ligresti G, Nicoletti F, Malaponte G, Traval S, McCubrey JA, Canevari S, Libra M. Yin Yang 1 overexpression in difuse large B-cell lymphoma is associated with B-cell transformation and tumor progression. Cell Cycle. 2010;9(3):557-563.
25. Green MR, Monti S, Dalla-Favera R, Pasqualucci L, Walsh NC, Schmidt-Supprian M, Kutok JL, Rodig SJ, Neuberg DS, Rajewsky K, Golub TR, Alt FW, Shipp MA, Manis JP. Signatures of murine B-cell development implicate Yy1 as a regulator of the germinal center-specifc program. Proc Natl Acad Sci USA. 2011;108(7):2873-2878.
26. Liu H, Schmidt-Supprian M, Shi Y, Hobeika E, Barteneva N, Jumaa H, Pelanda R, Reth M, Skok J, Rajewsky K. Yin Yang 1 is a critical regulator of B-cell development. Genes Dev. 2007;21(10):1179-1189.
27. Seligson D, Horvath S, Huerta-Yepez S, Hanna S, Garban H, Roberts A, Shi T, Liu X, Chia D, Goodglick L, Bonavida B. Expression of transcription factor Yin Yang 1 in prostate cancer. Int J Oncol. 2005;27(1):131-141.
28. Ren G, Zhang G, Dong Z, Liu Z, Li L, Feng Y, Su D, Zhang Y, Huang B, Lu J. Recruitment of HDAC4 by transcription factor YY1 represses HOXB13 to afect cell growth in AR-negative prostate cancers. Int J Biochem Cell Biol. 2009;41(5):1094-1101.
29. Deng Z, Wan M, Cao P, Rao A, Cramer SD, Sui G. Yin Yang 1 regulates the transcrip-tional activity of androgen receptor. Oncogene. 2009;28(42):3746-3757.
30. Sun C, Song C, Ma Z, Xu K, Zhang Y, Jin H, Tong S, Ding W, Xia G, Ding Q. Periostin identifed as a potential biomarker of prostate cancer by iTRAQ-proteomics analysis of prostate biopsy. Proteome Sci. 2011;9:22.
31. Brankin B, Skaar TC, Brotzman M, Trock B, Clarke R. Autoantibodies to the nuclear phosphoprotein nucleophosmin in breast cancer patients. Cancer Epidemiol Biomarkers Prev. 1998;7(12):1109-1115.
32. Begon DY, Delacroix L, Vernimmen D, Jack-ers P, Winkler R. Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells. J Biol Chem. 2005;280(26):24428-24434.
33. Allouche A, Nolens G, Tancredi A, Delacroix L, Mardaga J, Fridman V, Winkler R, Boniver J, Delvenne P, Begon DY. Te combined immuno-detection of AP-2alpha and YY1 transcription factors is associated with ERBB2 gene overexpres-sion in primary breast tumors. Breast Cancer Res. 2008;10(1):R9.
34. Powe DG, Akhtar G, Habashy HO, Abdel-Fatah T, Rakha EA, Green AR, Ellis IO. Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplifcation. Breast Cancer Res. 2009;11(6):R90.
35. Liu X, Abdelrahim M, Abudayyeh A, Lei P, Safe S. Te nonsteroidal anti-infammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression. Mol Cancer Ter. 2009;8(5):1207-1217.
36. de Nigris F, Botti C, de Chiara A, Rossiello R, Apice G, Fazioli F, Fiorito C, Sica V, Napoli C. Expression of transcription factor Yin Yang 1 in human osteo-sarcomas. Eur J Cancer. 2006;42(15):2420-2424.
37. de Nigris F, Rossiello R, Schiano C, Arra C, Williams-Ignarro S, Barbieri A, Lanza A, Balestrieri A, Giuliano MT, Ignarro LJ, Napoli C. Deletion of Yin Yang 1 protein in osteosarcoma cells on cell invasion and CXCR4/angiogenesis and metastasis. Cancer Res. 2008;68(6):1797-1808.
38. de Nigris F, Crudele V, Giovane A, Casamas-simi A, Giordano A, Garban HJ, Cacciatore F, Pentimalli F, Marquez-Garban DC, Petrillo A, Cito L, Sommese L, Fiore A, Petrillo M, Siani A, Barbieri A, Arra C, Rengo F, Hayashi T, Al-Omran M, Ignarro LJ, Napoli C. CXCR4/YY1 inhibition impairs VEGF network and angiogenesis during malignancy. Proc Natl Acad Sci U S A. 2010;107(32):14484-14489.
39. Abbondanza C, de Nigris F, De Rosa C, Rossiello R, Puca GA, Napoli C. Silencing of YY1 down- Nicholson et.al. regulates RIZ1 promoter in human osteosarcoma. Oncol Res. 2008;17(1):33-41.
40. Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Dahlman J, Cheng A, Hall BM, Qualman SJ, Chandler DS, Croce CM, Guttridge DC. NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell. 2008;14(5):369-381.
41. Baritaki S, Chatzinikola AM, Vakis AF, Soulitzis N, Karabetsos DA, Neonakis I, Bonavida B, Spandidos DA. YY1 Over-expression in human brain gliomas and meningiomas correlates with TGF-beta1, IGF-1 and FGF-2 mRNA levels. Cancer Invest. 2009;27(2):184-192.
42. Crea F, Hurt EM, Farrar WL. Clinical signifcance of Polycomb gene expression in brain tumors. Mol Cancer. 2010;9:265.
43. Chinnappan D, Xiao D, Ratnasari A, Andry C, King TC, Weber HC. Transcription factor YY1 expression in human gastrointestinal cancer cells. Int J Oncol. 2009;34(5):1417-1423.
44. Yokoyama NN, Pate KT, Sprowl S, Waterman ML. A role for YY1 in repression of dominant negative LEF-1 expression in colon cancer. Nucleic Acids Res. 2010;38(19):6375-6388.
45. Yang H, Li TW, Peng J, Mato JM, Lu SC. Insulin-like growth factor 1 activates methionine adenosyltrans-ferase 2A transcription by multiple pathways in human colon cancer cells. Biochem J. 2011;436(2):507-516.
46. Petrella BL, Brinckerhof CE. PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma. Cancer Biol Ter. 2009;8(14):1389-1401.
47. Shin E, Lee KB, Park SY, Kim SH, Ryu HS, Park YN, Yu E, Jang JJ. Gene expression profling of human hepatoblastoma using archived formalin-fxed and parafn-embedded tissues. Virchows Arch. 2011;458(4):453-465.
48. Zaravinos A, Lambrou GI, Boulalas I, Delakas D, Spandidos DA. Identifcation of common difer-entially expressed genes in urinary bladder cancer. PLoS One. 2011;6(4):e18135.
49. Grubach L, Juhl-Christensen C, Rethmeier A, Olesen LH, Aggerholm A, Hokland P, Ostergaard M. Gene expression profling of Polycomb, Hox and Meis genes in patients with acute myeloid leukaemia. Eur J Haematol. 2008;81(2):112-122.
50. Erkeland SJ, Valkhof M, Heijmans-Antonissen C, Delwel R, Valk PJ, Hermans MH, Touw I P. Te gene encoding the transcriptional regulator,Yin Yang 1 (YY1) is a myeloid transforming gene interfering with neutrophilic diferentiation. Blood. 2003;101(3):1111-1117.
51. O'Connor MJ, Tan SH, Tan CH, Bernard HU. YY1 represses human papillomavirus type 16, transcription by quenching AP-1 activity. J Virol. S 1996;70(10):6529-6539.
52. Lace MJ, Isacson C, Anson JR, Lorincz AT, Wilczynski SP, Haugen TH, Turek LP. Upstream regulatory region alterations found in human papil-lomavirus type 16 (HPV-16) isolates from cervical l carcinomas increase transcription, ori function, and HPV immortalization capacity in culture. J Virol,2009;83(15):7457-7466.
53. Lace MJ, Yamakawa Y, Ushikai M, Anson JR, Haugen TH, Turek LP. Cellular factor YY1 downregu- lates the human papillomavirus 16 E6/E7 promoter, P97, in vivo and in vitro from a negative element overlapping the transcription-initiation site. J Gens Virol. 2009;90(Pt 10):2402-2412.
54. Li Y, Wang F, Xu J, Ye F, Shen Y, Zhou J, Lu W, Wan X, Ma D, Xie X. Progressive miRNA expression profles in cervical carcinogenesis and identifcation of HPV-related target genes for miR-29. J Pathol. 2011;224(4):484-495.
55. Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, Murphy S, Dressman HK, Febbo PG, West M, Nevins JR, Marks JR. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res. 2005;11(10):3686-3696.
56. Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, Libermann TA, Cannistra SA. Gene,expression signature with independent prognostic signifcance in epithelial ovarian cancer. J Clin Oncol. 2004;22(23):4700-4710.
57. Matsumura N, Huang Z, Baba T, Lee PS, Barnett JC, Mori S, Chang J T, Kuo WL, Gusberg AH, Whitaker RS, Gray JW, Fujii S, Berchuck A, Murphy SK. Yin L yang 1 modulates taxane response in epithelial ovar- ian cancer. Mol Cancer Res. 2009;7(2):210-220.